GlassScriptPhysician profile
Keval V Patel
NPI 1023362787
$9,839.57
in general payments reported to CMS, 2019-2025
47 companies · $2,060 in 2025
The $2,060 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $739 · 2021: $1,647 · 2022: $1,852 · 2023: $1,584 · 2024: $1,132 · 2025: $2,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,756 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,755.77 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $915.20 | 2019-2025 | Watchman Flx, Watchman, Lux-Dx Insertable Cardiac Monitor |
| Novartis Pharmaceuticals Corporation | $639.33 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $623.53 | 2019-2024 | Xarelto |
| Cvrx, INC. | $600.01 | 2021-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $589.48 | 2021-2025 | Verquvo, Capvaxive, Belsomra |
| Pfizer INC. | $546.27 | 2020-2025 | |
| Abbott Laboratories | $462.77 | 2019-2024 | Jot Dx, Amplatzer |
| Alnylam Pharmaceuticals INC. | $434.30 | 2022-2025 | Onpattro |
| Impulse Dynamics (USA) INC. | $427.85 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $424.93 | 2019-2025 | Farxiga |
| Kestra Medical Technology Services, INC. | $391.05 | 2024-2025 | Assure Wcd |
| Amgen INC. | $358.40 | 2019-2025 | Repatha, Repatha |
| Penumbra, INC. | $269.21 | 2022-2025 | Indigo System |
| Amarin Pharma, INC. | $263.86 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $257.71 | 2019-2025 | Camzyos, Eliquis |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $238.83 | 2023-2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.66 | 2021-2025 | Jardiance |
| Biotronik INC. | $197.98 | 2022-2025 | Acticor 7 Vr-T Dx, Amvia Edge |
| Sanofi-Aventis U.S. LLC | $186.35 | 2019-2024 | |
| Shockwave Medical, INC | $179.82 | 2023 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Edwards Lifesciences Corporation | $133.73 | 2019-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Daiichi Sankyo INC. | $127.84 | 2021-2023 | Injectafer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $127.28 | 2020-2025 | Lifevest |
| Kowa Pharmaceuticals America, INC. | $126.46 | 2019-2022 | |
| Cardiovascular Systems INC. | $124.05 | 2019 | |
| Heartflow, INC. | $123.53 | 2025 | |
| Esperion Therapeutics, INC. | $119.25 | 2021-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $104.62 | 2021-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $74.87 | 2022-2023 | Arcalyst |
| Philips North America LLC | $70.23 | 2022-2023 | |
| Novo Nordisk INC | $68.46 | 2022-2024 | Wegovy |
| Akcea Therapeutics, INC. | $58.24 | 2020-2021 | |
| Lexicon Pharmaceuticals, INC. | $47.67 | 2023 | Inpefa |
| Bridgebio Pharma, INC. | $36.24 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $35.69 | 2024 | Arcalyst |
| Lilly USA, LLC | $35.19 | 2025 | Mounjaro, Zepbound |
| Medtronic, INC. | $29.64 | 2022-2024 | Aurora Ev-Icd Mri Surescan |
| United Therapeutics Corporation | $27.14 | 2023 | Orenitram, Tyvaso |
| Regeneron Healthcare Solutions, INC. | $27.09 | 2019-2021 | |
| Organogenesis INC. | $20.67 | 2021 | |
| Altathera Pharmaceuticals LLC | $18.02 | 2025 | Sotalol Hydrochloride |
| Tactile Systems Technology INC | $17.25 | 2023 | Entre Plus, Flexitouch Plus |
| Ionis Pharmaceuticals, INC. | $15.16 | 2025 | Tryngolza |
| Amryt Pharma Holdings LTD | $14.86 | 2021 | |
| Biocompatibles, INC. | $14.62 | 2019 | |
| Glaxosmithkline, LLC. | $14.14 | 2019 | |
| Si-Bone, INC. | $14.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keval Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.